Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BP-294 (Ste Civile Bioprojet).

J R Fozard1

  • 1Research Department, Novartis Pharma AG, Building 386/1035, Postfach, CH-4002 Basel, Switzerland. john_r.fozard@pharma.novartis.com

Idrugs : the Investigational Drugs Journal
|August 2, 2005
PubMed
Summary

BP-294, a histamine-H(3) agonist, is being developed as an asthma treatment. This drug candidate is currently in phase II clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of sphingosine-1-phosphate (S1P) and the S1P(2) receptor in allergen-induced, mast cell-dependent contraction of rat lung parenchymal strips.

Naunyn-Schmiedeberg's archives of pharmacology·2009
Same author

In vivo pharmacological evaluation of compound 48/80-induced airways oedema by MRI.

British journal of pharmacology·2008
Same author

Capsaicin-induced mucus secretion in rat airways assessed in vivo and non-invasively by magnetic resonance imaging.

British journal of pharmacology·2007
Same author

Effects of endotoxin and allergen alone and in combination on the sensitivity of the rat airways to adenosine.

Autonomic & autacoid pharmacology·2005
Same author

Suppression of histamine-induced tachypnoea in the rhesus monkey by sibenadet: no role for dopamine D2 receptors.

Autonomic & autacoid pharmacology·2004
Same author

Airway hyperresponsiveness to bradykinin induced by allergen challenge in actively sensitised Brown Norway rats.

Naunyn-Schmiedeberg's archives of pharmacology·2004

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Drug Development

Background:

  • Asthma is a chronic respiratory disease characterized by airway inflammation and bronchoconstriction.
  • Histamine H3 receptors play a role in regulating airway function.
  • Novel therapeutic targets are needed for effective asthma management.

Purpose of the Study:

  • To evaluate the potential of BP-294, a histamine-H3 agonist, as a treatment for asthma.
  • To assess the safety and efficacy of BP-294 in ongoing clinical trials.

Main Methods:

  • BP-294, a prodrug of R-alpha-methylhistamine, acts as a histamine-H3 agonist.
  • The drug is currently undergoing phase II clinical trials.
  • Clinical trial methodology involves assessing therapeutic effects in asthma patients.

Main Results:

  • BP-294 is under active investigation for its therapeutic potential in asthma.
  • Phase II clinical trials are underway to determine efficacy and safety.
  • Preliminary data is expected from ongoing studies.

Conclusions:

  • BP-294 represents a novel therapeutic approach for asthma.
  • Further clinical evaluation is necessary to establish its role in asthma treatment.
  • The development of BP-294 highlights ongoing research into histamine receptor modulation for respiratory diseases.

Related Experiment Videos